Premium
End‐stage renal disease and severe aortic stenosis. Does valve replacement improve one‐year outcomes?
Author(s) -
Alraies M. Chadi,
Satler Lowell F.
Publication year - 2017
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27112
Subject(s) - medicine , stenosis , cardiology , aortic valve replacement , end stage renal disease , stage (stratigraphy) , aortic valve stenosis , valve replacement , disease , surgery , paleontology , biology
Key Points TAVR or SAVR has a 1‐year survival benefit over BAV alone in patients with severe symptomatic AS and ESRD on dialysis More studies comparing SAVR vs. TAVR outcome in ESRD patients and severe AS are needed to understand further the patients that will benefit the most in terms of quality of life. The heart team approach for treatment of patients with ESRD and severe AS remains extremely important to optimize patient's outcome.